A

AbbVie

Global biopharmaceutical company developing medicines

Publications Manager Immunology

Full-TimeUpdated
$109.5k - $208.5k/yr+ Long-term incentive program
Mid, Senior
Bachelor's, Master's, PharmD, PhD
Waltham, MA, USA
Hybrid
Content & WritingTechnical Writing

About the job

Requirements
  • A bachelor's degree is required.
  • Four to five years of medical or scientific publications (or related) experience is required.
  • Pharmaceutical industry or related experience, such as experience at a medical communications agency, is required.
  • Demonstrated abilities in a leadership capacity are required.
  • Ability to understand and interpret medical data is required.
  • Working knowledge of statistical concepts and techniques is required.
  • Knowledge of clinical and scientific publication structure, content, and quality is required.
  • Knowledge of scientific publication regulations and best practices is required.
  • Excellent written and verbal communication skills, including demonstrated success creating and delivering effective presentations to senior-level audiences, are required.
  • Ability to form, maintain, and lead productive cross-functional working teams, including addressing issues that arise, is required.
  • Microsoft Office and internet navigation proficiency are required.
Responsibilities
  • Lead cross-functional Publications Teams for assigned assets, including leading team meetings and discussions and driving execution of publication plans while incorporating input from key global stakeholders.
  • Lead tactical execution of publication plans, including clinical manuscripts, abstracts, posters, and oral presentations, while meeting established timelines and budgets.
  • Review publications in the assigned therapeutic area to ensure quality and alignment with Scientific Communication Platforms and supporting communications.
  • Partner with the Scientific Communications Director to ensure transfer of the scientific publications strategic plan and oversee its implementation through publication plans and supporting tactics.
  • Partner with the Publications Director to project and manage outsourcing budgets and internal resource needs for assigned assets.
  • Provide managerial oversight to internal and external medical writers on assigned projects, ensuring high-quality and timely work and adherence to Publication Policy and associated procedures.
  • Direct external vendors in executing publication projects within specified timelines and ensure quality publication deliverables.
  • Ensure performance assessments for direct reports are completed; provide training and feedback, resolve personnel issues, and manage talent retention for assigned staff.
  • Address and resolve publication-related issues for assigned therapeutic areas and assets.
  • Ensure project information in publication records and resourcing tools is accurate and up to date.
Desired Qualifications
  • A PhD, PharmD, or master's degree is preferred.
  • Knowledge of the product therapeutic area is preferred.
  • A relevant professional certification or credential, such as CMPP or AMWA, is a plus.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

3%

1 year growth

4%

2 year growth

4%
Yahoo Finance
Oct 30th, 2026
CDs yield 1.76% while AbbVie lifts its dividend to $1.82: which suits retirees?

AbbVie raised its quarterly dividend to $1.82 from $1.73 per share on October 30, 2026, a raise no certificate of deposit (CD) can match. The national average yield on a 12-month CD was 1.76% as of October 1, 2026, and a bank cannot cut that rate during the term. Dividends carry risk, though. Companies can cut payouts, and share prices can fall. Johnson & Johnson has raised its dividend for 64 straight years, and Procter & Gamble for 70. Tax also matters. CD interest is taxed as ordinary income, while qualified dividends face rates of 0%, 15%, or 20%. That edge disappears inside a traditional individual retirement account (IRA).

PR Newswire
Oct 30th, 2026
AbbVie Q3 revenue up 10.3% to $17.4B, raises 2026 EPS guidance

AbbVie reported third-quarter net revenues of $17.404 billion, up 10.3% on a reported basis and 10.5% at constant currency. Diluted earnings per share (EPS) rose over 100% to $2.37 on a GAAP basis, while adjusted EPS was $3.82. Immunology revenues grew 16.3% to $9.165 billion, led by Skyrizi at $5.776 billion and Rinvoq at $2.706 billion. Neuroscience revenues rose 19.4% to $3.389 billion. Oncology rose 0.8% to $1.696 billion, and aesthetics fell 1.4% to $1.176 billion. The company completed its acquisition of Apogee Therapeutics and raised its 2026 adjusted EPS guidance to $13.95–$13.99, from $13.76–$13.96. It also announced a 5.2% dividend increase, starting with the payment due in February 2027.

Yahoo Finance
Oct 28th, 2026
Abbott Laboratories sees $23.9M net ETF inflow as 25 funds buy

ETFs bought a net $23.9 million of Abbott Laboratories stock on Monday, reversing a $3.3 million outflow the previous trading day. Twenty-five funds were buyers, nine sold, and 127 held steady. IHI led the buying with $14.1 million, lifting its stake by 2.22% to 6,170,459 shares. XLV added $9.5 million and DFLV $2.1 million. Over the past five sessions, ETFs were net buyers on three days and net sellers on two. Abbott has a market cap of $178.4 billion. Trailing 12-month revenue was $48.23 billion, up 8.2% year on year. The shares trade at $103.10 and are down 15.67% this year.

Yahoo Finance
Oct 24th, 2026
AbbVie wins FDA nod for at-home Skyrizi starts in Crohn's; sales boost seen after 60-90 days

AbbVie won US Food and Drug Administration (FDA) approval on October 23 for an at-home start to Skyrizi in adults with moderately to severely active Crohn's disease. Patients previously had to begin with intravenous infusions; they can now take the first doses at home with an on-body injector. By Week 12, 74% of patients new to advanced therapy reached clinical remission, against 27% on placebo. Johnson & Johnson's rival Tremfya won similar approval about 19 months earlier. Chief commercial officer Jeff Stewart said full paid access "will probably take 60 or 90 days" because insurers must approve the regimen. Sales impact should therefore come mostly after the fourth quarter. AbbVie reports third-quarter results on October 30. It guides for revenue of about $17.2 billion; Skyrizi's franchise sold $17.562 billion in 2025.

Yahoo Finance
Oct 23rd, 2026
ETFs net sell $42.1M of AbbVie as XLV leads $32.0M exit

Exchange-traded funds (ETFs) were net sellers of AbbVie shares for a second straight session, selling a net $42.1 million on October 21. Sellers moved larger sums even though more funds bought than sold: 24 ETFs added shares and 23 cut them. The Health Care Select Sector SPDR Fund led the selling with $32.0 million, followed by iShares Core S&P 500 ETF at $9.3 million and SPDR S&P 500 ETF Trust at $2.0 million. On October 20, ETFs sold a net $6.7 million, after three days of net buying. AbbVie has a market cap of $504.0 billion. Trailing 12-month revenue was $64.39 billion, up 10.3% over the past year.